Core Viewpoint - IGC Pharma has announced a change in its fiscal year end from March 31 to December 31, effective December 31, 2025, to enhance engagement with U.S. investors [1] Company Summary - IGC Pharma is a clinical-stage pharmaceutical company focused on developing innovative treatments for Alzheimer's disease using Artificial Intelligence [1] - The decision to change the fiscal year end is described as a straightforward but important step by the CEO, Ram Mukunda [1]

Core Viewpoint - IGC Pharma, Inc. is set to host a conference call and webcast to discuss its operational progress for the second quarter and mid-year period ending September 30, 2025 [1] Company Summary - IGC Pharma is a clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease using AI technology [1] - The conference call is scheduled for November 17, 2025, at 11:00 a.m. Eastern Time [1]